Italia markets closed

Erasca, Inc. (ERAS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,06000,0000 (0,00%)
Alla chiusura: 04:00PM EDT
2,1000 +0,04 (+1,94%)
Dopo ore: 05:33PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,0600
Aperto2,4200
Denaro2,0400 x 200
Lettera2,0600 x 200
Min-Max giorno2,0300 - 2,5880
Intervallo di 52 settimane1,5100 - 3,3750
Volume1.854.192
Media Volume778.688
Capitalizzazione311,239M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-0,8300
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,50
  • GlobeNewswire

    Erasca to Present at the Cantor Global Healthcare Conference

    SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 26, 2023, at 8:10 am Eastern Time at the Cantor Global Healthcare Conference, which is being held at the InterContinental New York Barclay in New York, New York. M

  • GlobeNewswire

    Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

    SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in a fireside chat on Tuesday, September 12, 2023, at 5:30 pm Eastern Time at the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Hotel in New York, N

  • GlobeNewswire

    Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

    Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in Q2-Q4 2024 Dosing of first patient in pivotal SEACRAFT-2 trial in NRAS-mutant melanoma expected in H1 2024 SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapie